The Utility of Micro-RNA

MicroRNAs have demonstrated roles in human development, where their expression can drive or maintain tissue phenotype. Correspondingly their aberrant expression is a significant driver of the pathophysiology of many chronic diseases including diabetes and cancer. miRNA's are recognised as being highly stable ex vivo and miRNA signatures can be obtained from samples with poor ribosome integrity number (RIN) values. When this is combined with their undisputed biological importance it makes miRNA’s attractive biomarker candidates for a wide range of applications.

The utility of miRNA provides a means to generate cost-effective, information-rich cell characterisation tools and biomarkers for use in the Bioprocessing, Cell and Stem Cell Therapy, and Drug Discovery and Development markets. Click to find out how our innovative miRNA products can help you

About Sistemic

Sistemic is a development-stage biomedical company focused on the analysis of the information content of microRNA and other non-coding RNAs for applications in the development of cell therapies and drug repositioning. Sistemic’s patented and proprietary technology platforms provide a novel way to apply the information content of miRNA’s to overcome key obstacles to creating clinically useful stem cell therapies.

Recent News

Sistemic announce new miRNA publication exploring the functional differences between MSCs derived from different tissues and the continued expansion of patent portfolio in the exosome and predictive biomarker space.

Release Date: October 5, 2016

Glasgow, Scotland. Sistemic Ltd. announced today that it has recently published, in collaboration with colleagues at Institute of Infection, Inflammation and Immunity, Glasgow Biomedical Research Centre, University of Glasgow, evidence of significant and potentially functionally relevant differences between MSCs from Olfactory Mucosa and from Bone Marrow revealed by miRNA profiling.

Sistemic announce ground breaking predictive diagnostic assay for protein production in a cell

Release Date: May 16, 2016


Glasgow, Scotland. Sistemic Ltd. today announced the launch of its first predictive diagnostic product for protein production utilising its novel miRNA technologies including SistemQC™, SistemSeek™ and SistemExpress™. The introduction of the first product in the new SistemCheck™ range will be for the prediction of indoleamine 2,3-dioxygenase (IDO) production in cells. 

Sistemic and Cynata announce cooperation on in-process purity assay development for Cell Therapy (CT) product.

Release Date: May 6, 2016


Glasgow, Scotland and Victoria, Australia.

Sistemic Ltd. and Cynata Therapeutics Limited (ASX:CYP) announced today that they have entered into an agreement which will see Sistemic use its novel SistemQC™ miRNA technology platforms, together with its extensive internal databases of cellular products to develop an in-process assessment assay for Cynata’s unique Cymerus™ Cell Therapy (CT) products.

Sistemic and RoosterBio Inc Announce broad Collaboration Agreement to Advance miRNA and Mesenchymal Stem/Stromal Cell (MSC) Regenerative Technology

Release Date: May 28, 2015


Frederick, MD, USA March 28, 2015 Sistemic Ltd. and RoosterBio Inc. announced today that they have entered into a commercial collaboration agreementand signed a memorandum of understanding whereby both companies will combine their technologies and work together towards advancing the field of mesenchymal stem/stromal cell (MSC) regenerative technology.